| Scrip Code | 532331 |
|---|---|
| NSE Symbol | AJANTPHARM |
| MSEI Symbol | NOTLISTED |
| ISIN | INE031B01049 |
| Name of company | Ajanta Pharma Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 30-01-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 12-01-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmacutical |
| Start date and time of board meeting | 30-01-2026 13:30:00 |
| End date and time of board meeting | 30-01-2026 15:00:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Nosuchdefault | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 1,20,659.00 | 3,63,539.00 | |
| Other income | 2,576.00 | 14,142.00 | |
| Total income | 1,23,235.00 | 3,77,681.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 23,507.00 | 65,975.00 |
| (b) | Purchases of stock-in-trade | 5,789.00 | 16,007.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (3,823.00) | (776.00) |
| (d) | Employee benefit expense | 30,616.00 | 88,056.00 |
| (e) | Finance costs | 187.00 | 333.00 |
| (f) | Depreciation, depletion and amortisation expense | 4,238.00 | 12,461.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 30,475.00 | 98,283.00 |
| Total other expenses | 30,475.00 | 98,283.00 | |
| Total expenses | 90,989.00 | 2,80,339.00 | |
| 3 | Total profit before exceptional items and tax | 32,246.00 | 97,342.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 32,246.00 | 97,342.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 7,258.00 | 20,928.00 |
| 8 | Deferred tax | 484.00 | 1,460.00 |
| 9 | Total tax expenses | 7,742.00 | 22,388.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 24,504.00 | 74,954.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 24,504.00 | 74,954.00 |
| 17 | Other comprehensive income net of taxes | 19.00 | (259.00) |
| 18 | Total Comprehensive Income for the period | 24,523.00 | 74,695.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,507.00 | 2,507.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 19.61 | 60 | |
| Diluted earnings (loss) per share from continuing operations | 19.61 | 59.99 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 19.61 | 60 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 19.61 | 59.99 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above standalone unaudited results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2026. The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine month period ended 31 December 2025. The review report has been filed with the stock exchange and is available on company website. 2.Other income / Other expense includes:- Rs in Crore Particular Quarter ended Nine Month ended Year ended 31-Dec-25 30-Set-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 Dividend from Subsidiaries - 15.21 - 36.68 22.28 22.28 (in other income) Foreign exchange gain 9.42 41.52 20.72 53.50 30.73 32.96 (in other income) Foreign exchange loss - 40.95 - 61.34 13.88 8.82 (in other expenses) 3. During nine month ended 31 December 2025, 23,525 (previous year 25,325) equity shares of Rs 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs 47,050 (previous year Rs 50,650) and securities premium by Rs 3.50 crores (previous year Rs 3.84 crores).Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) are being vested and will be settled in cash. Hence, there will not be any change in the paid-up share capital and securities premium of the company on account of SARs. 4. In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Company. The Company has not yet received any formal communication from the Income Tax Authorities in this regard and hence no adjustments have been made in the standalone financial results for the quarter and period ended 31 December 2025. 5. The Government of India has announced four Labour Code and have made them effective from 21st November, 2025. The corresponding all supporting rules under these codes are yet to be notified. The company is in the process of evaluating the full impact of these new labour codes announced. The company has estimated and accounted for incremental liability for own employees and the Company continues to monitor the finalisation of Central/State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 6.The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals. 7. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Re-measurement of defined benefit liability/(assets) | 28.00 | (399.00) |
| Total Amount of items that will not be reclassified to profit and loss | 28.00 | (399.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 9.00 | (140.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 19.00 | (259.00) |
| Whether results are audited or unaudited | Unaudited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | B S R & Co. LLP | Yes | 31-07-2025 | ||
|---|---|---|---|---|---|